Analysis of CT Perfusion Blood Flow Maps in Patients with Lung Cancer: Correlation with the Overall Survival

Computed Tomography perfusion (CTp) is a functional imaging technique with a wide application in the oncological field. CTp allows detecting the presence of tumour abnormal hemodynamic patterns, by analysing the tissue temporal variations occurring after the administration of the contrast medium. This work presents a novel approach to extract meaningful features from blood flow (BF) maps of lung cancers, which could act as a prognostic image-based biomarker.

[1]  K. Miles,et al.  Perfusion CT for the assessment of tumour vascularity: which protocol? , 2003, The British journal of radiology.

[2]  Balaji Ganeshan,et al.  Quantifying tumour heterogeneity with CT , 2013, Cancer imaging : the official publication of the International Cancer Imaging Society.

[3]  Eun Sook Ko,et al.  Breast cancer heterogeneity: MR Imaging Texture Analysis and Survival Outcomes1 , 2016 .

[4]  B. Solomon,et al.  Lung cancer prognostic index: a risk score to predict overall survival after the diagnosis of non-small-cell lung cancer , 2017, British Journal of Cancer.

[5]  V. Goh,et al.  Primary esophageal cancer: heterogeneity as potential prognostic biomarker in patients treated with definitive chemotherapy and radiation therapy. , 2013, Radiology.

[6]  A. Bevilacqua,et al.  CT Perfusion in Patients with Lung Cancer: Squamous Cell Carcinoma and Adenocarcinoma Show a Different Blood Flow , 2018, BioMed research international.

[7]  K. Rabe,et al.  Management of non-small-cell lung cancer: recent developments , 2013, The Lancet.

[8]  Alessandro Bevilacqua,et al.  Automatic detection of misleading blood flow values in CT perfusion studies of lung cancer , 2016, Biomed. Signal Process. Control..

[9]  Chris R Chatwin,et al.  Hepatic enhancement in colorectal cancer: texture analysis correlates with hepatic hemodynamics and patient survival. , 2007, Academic Radiology.

[10]  K. Miles,et al.  Tumour heterogeneity in non-small cell lung carcinoma assessed by CT texture analysis: a potential marker of survival , 2012, European Radiology.

[11]  N. Tanner,et al.  Lung cancer: Progress in diagnosis, staging and therapy , 2010, Respirology.

[12]  K. Miles,et al.  Can CT measures of tumour heterogeneity stratify risk for nodal metastasis in patients with non-small cell lung cancer? , 2017, Clinical radiology.

[13]  Perry J Pickhardt,et al.  CT Texture Analysis: Definitions, Applications, Biologic Correlates, and Challenges. , 2017, Radiographics : a review publication of the Radiological Society of North America, Inc.

[14]  Balaji Ganeshan,et al.  Imaging heterogeneity in gliomas using texture analysis. , 2011 .

[15]  Kwok-Kin Wong,et al.  Non-small-cell lung cancers: a heterogeneous set of diseases , 2014, Nature Reviews Cancer.

[16]  Bal Sanghera,et al.  Assessment of tumor heterogeneity: an emerging imaging tool for clinical practice? , 2012, Insights into Imaging.

[17]  Antonella Petrillo,et al.  A geometrical perspective on the 3TP method in DCE-MRI , 2015, Biomed. Signal Process. Control..

[18]  M. Bellomi,et al.  CT perfusion in oncology: how to do it , 2010, Cancer imaging : the official publication of the International Cancer Imaging Society.

[19]  K. Miles,et al.  Perfusion CT: a worthwhile enhancement? , 2003, The British journal of radiology.

[20]  V. Goh,et al.  Assessment of primary colorectal cancer heterogeneity by using whole-tumor texture analysis: contrast-enhanced CT texture as a biomarker of 5-year survival. , 2013, Radiology.

[21]  G. Warnock,et al.  Comparison of Contrast-Enhanced CT and [18F]FDG PET/CT Analysis Using Kurtosis and Skewness in Patients with Primary Colorectal Cancer , 2017, Molecular Imaging and Biology.

[22]  Patrick Granton,et al.  Radiomics: extracting more information from medical images using advanced feature analysis. , 2012, European journal of cancer.

[23]  Hongliang Sun,et al.  Assessment of Relationship Between CT Features and Serum Tumor Marker Index in Early-stage Lung Adenocarcinoma. , 2016, Academic radiology.

[24]  Alessandro Bevilacqua,et al.  Quantitative assessment of effects of motion compensation for liver and lung tumors in CT perfusion. , 2014, Academic radiology.

[25]  J. Remy,et al.  Perfusion CT allows prediction of therapy response in non-small cell lung cancer treated with conventional and anti-angiogenic chemotherapy , 2013, European Radiology.

[26]  T-Y Lee,et al.  CT imaging of angiogenesis. , 2003, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[27]  V. Goh,et al.  Perfusion CT imaging of treatment response in oncology. , 2015, European journal of radiology.

[28]  Alessandro Bevilacqua,et al.  A novel approach for semi-quantitative assessment of reliability of blood flow values in DCE-CT perfusion , 2017, Biomed. Signal Process. Control..

[29]  M. Maurin,et al.  REVIEW ARTICLE doi: 10.1111/j.1472-8206.2008.00633.x The Hill equation: a review of its capabilities in pharmacological modelling , 2008 .

[30]  D. Sahani,et al.  CT perfusion as an imaging biomarker in monitoring response to neoadjuvant bevacizumab and radiation in soft-tissue sarcomas: comparison with tumor morphology, circulating and tumor biomarkers, and gene expression. , 2015, AJR. American journal of roentgenology.

[31]  Julia F. Barrett,et al.  Artifacts in CT: recognition and avoidance. , 2004, Radiographics : a review publication of the Radiological Society of North America, Inc.

[32]  Fabian Kiessling,et al.  Estimation of tissue perfusion by dynamic contrast-enhanced imaging: simulation-based evaluation of the steepest slope method , 2010, European Radiology.

[33]  Alessandro Bevilacqua,et al.  Automatic classification of lung tumour heterogeneity according to a visual-based score system in dynamic contrast enhanced CT sequences , 2016 .

[34]  Pierre Bedossa,et al.  Pancreatic endocrine tumors: tumor blood flow assessed with perfusion CT reflects angiogenesis and correlates with prognostic factors. , 2009, Radiology.

[35]  Takeshi Yoshikawa,et al.  Dynamic contrast-enhanced perfusion area-detector CT assessed with various mathematical models: Its capability for therapeutic outcome prediction for non-small cell lung cancer patients with chemoradiotherapy as compared with that of FDG-PET/CT. , 2017, European journal of radiology.